Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35552728.
- Also identified by DOI 10.1001/jamanetworkopen.2022.5996 and PMC identifier 9099425.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This case series examines numbers of US clinicians receiving waivers from the Drug Enforcement Administration allowing them to prescribe buprenorphine for opioid use disorder before and during the COVID-19 pandemic.
Medical subject headings
- Buprenorphine
- COVID-19
- Opioid-Related Disorders